Switchover study of onabotulinumtoxinA to incobotulinumtoxinA for facial dystonia.

John C BladenMaribel FavorAndre LitwinRaman Malhotra

Published in: Clinical & experimental ophthalmology (2020)

Switching from onabotulinumtoxinA to incobotulinumtoxinA did not result in an inferior outcome for the treatment of facial dystonia and led to a cost-saving for the department.

Keyphrases

deep brain stimulation
early onset
soft tissue
combination therapy